Humankind Investments LLC Grows Stake in Biogen Inc. (NASDAQ:BIIB)

Humankind Investments LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 32.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,010 shares of the biotechnology company’s stock after acquiring an additional 739 shares during the quarter. Humankind Investments LLC’s holdings in Biogen were worth $460,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in shares of Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 141 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in Biogen in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC lifted its position in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 186 shares during the last quarter. OFI Invest Asset Management bought a new position in shares of Biogen in the 4th quarter worth $32,000. Finally, SRS Capital Advisors Inc. purchased a new stake in shares of Biogen during the 4th quarter valued at $33,000. Institutional investors own 87.93% of the company’s stock.

Insider Activity

In other news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Biogen Stock Down 0.2 %

Shares of NASDAQ:BIIB opened at $118.20 on Friday. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The stock has a fifty day simple moving average of $128.33 and a two-hundred day simple moving average of $144.38. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $238.00. The stock has a market capitalization of $17.32 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 1.51 and a beta of 0.12.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The firm had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same quarter in the previous year, the firm earned $3.67 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIIB has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on Biogen from $185.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday, May 5th. Sanford C. Bernstein assumed coverage on Biogen in a research report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price objective on the stock. Citigroup dropped their target price on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. The Goldman Sachs Group reduced their price target on shares of Biogen from $219.00 to $197.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a research report on Friday, May 2nd. Twenty investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $191.30.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.